IGC PHARMA, INC. — Earnings

Most recent reported period: FY2025 (Q3) (filed for period ending 2025-09-30) · sourced from SEC EDGAR

Next earnings (estimated): Tue, December 30, 2025 129 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)

Recent earnings · last 8 quarters

Quarter endRevenueYoYNet IncomeYoYOp. Margin
2025-09-30$191K↓-53.6%$-2M↓-6.1%-1517.8%
2025-06-30$328K↑+20.6%$-2M↑+32.8%-580.8%
2025-03-31$330K↑+11.9%
2024-12-31$257K↑+26.0%$-2M↑+67.3%-730.7%
2024-09-30$412K↑+41.6%$-2M↑+29.9%-427.2%
2024-06-30$272K↓-51.0%$-2M↓-14.6%-880.9%
2024-03-31$295K↑+39.2%
2023-12-31$204K↓-38.6%$-6M↓-148.5%-1469.6%

Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.

Last earnings · FY2025 (Q3)

Revenue
$191K
↓-53.6% -$221K YoY

Earnings surprise · last 8 quarters

YoY % change · proxy for analyst surprise until estimates land

EPS history · last 10 fiscal years

diluted, GAAP, annual

Note: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.

Margin trends · 63 quarters

margin trajectory tells the operating-leverage story
Gross Margin↑+3.8pts
51.8%
Operating Margin↓-1090.6pts
-1517.8%
Net Margin↓-536.7pts
-953.4%

Go deeper